LEO Pharma Advances Delgocitinib Cream to Phase 3 Trial for Lichen Sclerosus
Event summary
- LEO Pharma initiated the DELTA CARE 1 phase 3 trial for delgocitinib cream (Anzupgo) in lichen sclerosus (LS).
- The trial will enroll up to 652 adult patients across 80-90 sites in North America, Europe, and Canada.
- The primary endpoint is the Investigator’s Global Assessment for LS treatment success (IGA-LS TS) after 12 weeks.
- Anzupgo is currently approved for chronic hand eczema (CHE) in the U.S., EU, and several other markets.
- LEO Pharma obtained exclusive rights to delgocitinib for topical dermatological indications in 2014, excluding Japan.
The big picture
LEO Pharma's move to expand Anzupgo’s indication into lichen sclerosus represents a strategic effort to address a significant unmet medical need and diversify its revenue streams beyond chronic hand eczema. The lack of approved treatments for LS creates a substantial market opportunity, but success will depend on demonstrating efficacy and safety in the phase 3 trial. This expansion also underscores the broader trend of pharmaceutical companies seeking to repurpose existing drugs for new indications to accelerate development timelines and reduce costs.
What we're watching
- Clinical Efficacy
- The trial's success hinges on demonstrating statistically significant efficacy for LS, a condition with limited treatment options, which will be critical for broader adoption.
- Regulatory Approval
- Approval in the U.S. and Europe will depend on the DELTA CARE 1 trial results and could significantly expand Anzupgo’s market reach, given the disease’s prevalence.
- Competitive Landscape
- Other pharmaceutical companies may be developing competing therapies for LS, and LEO Pharma’s ability to secure market share will depend on the trial’s outcome and commercialization strategy.
Related topics